Moomoo AI 已提取核心信息
On December 31, 2023, Altimmune Inc. was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission (SEC), indicating a change in ownership by certain entities and individuals. The filing was made under Rule 13d-1(c), which is used for persons who have acquired beneficial ownership of more than 5% of a class of equity securities of a public company. The entities and individuals listed in the filing include Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Master Fund LP, David Witzke, and Michael Gregory. All parties reported owning 0 shares and thus, 0.0% of the class of common stock of Altimmune Inc. The filing also indicated that as...Show More
On December 31, 2023, Altimmune Inc. was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission (SEC), indicating a change in ownership by certain entities and individuals. The filing was made under Rule 13d-1(c), which is used for persons who have acquired beneficial ownership of more than 5% of a class of equity securities of a public company. The entities and individuals listed in the filing include Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Master Fund LP, David Witzke, and Michael Gregory. All parties reported owning 0 shares and thus, 0.0% of the class of common stock of Altimmune Inc. The filing also indicated that as of the date of the filing, the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities. The principal business address for the entities and individuals is located in Dallas, Texas, with the exception of Avidity Master Fund LP, which is based in the Cayman Islands. The filing includes a certification that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
2023年12月31日，Altimmune Inc.成为向美国证券交易委员会（SEC）提交的附表13G文件的主体，该文件表明某些实体和个人的所有权发生了变化。该申请是根据第13d-1（c）条提交的，该规则适用于已获得上市公司某类股权证券5％以上的受益所有权的人。文件中列出的实体和个人包括Avidity Partners Management LP、Avidity Partners Management（GP）有限责任公司、Avidity Capital Partners（GP）有限责任公司、Avidity Master Fund LP、David Witzke和Michael Gregory。...展开全部
2023年12月31日，Altimmune Inc.成为向美国证券交易委员会（SEC）提交的附表13G文件的主体，该文件表明某些实体和个人的所有权发生了变化。该申请是根据第13d-1（c）条提交的，该规则适用于已获得上市公司某类股权证券5％以上的受益所有权的人。文件中列出的实体和个人包括Avidity Partners Management LP、Avidity Partners Management（GP）有限责任公司、Avidity Capital Partners（GP）有限责任公司、Avidity Master Fund LP、David Witzke和Michael Gregory。所有各方均报告拥有0股股份，因此占Altimmune Inc.普通股类别的0.0％。该文件还显示，截至申报之日，申报人已不再是该类别超过5％的证券的受益所有人。除总部设在开曼群岛的Avidity Master Fund LP外，这些实体和个人的主要营业地址位于德克萨斯州的达拉斯。该文件包括一份证明，证明这些证券是在正常业务过程中收购的，不是为了改变或影响发行人的控制权。
有用
没用